永利3044(中国集团)有限公司官网

Zervimesine (CT1812) 是一种口服有效且能透过血脑屏障的sigma-2受体拮抗剂，在阿尔茨海默病研究中具有潜在治疗价值。

/

2~8℃避光保存，有效期3年。

[1] Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H 3rd, Spires-Jones TL, Cirrito JR, Catalano SM. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimers Dement. 2021 Aug;17(8):1365-1382. doi: 10.1002/alz.12302. Epub 2021 Feb 8. PMID: 33559354; PMCID: PMC8349378.